-
1
-
-
24944480788
-
The Akt-mTOR tango and its relevance to cancer
-
Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8 (2005) 179-183
-
(2005)
Cancer Cell
, vol.8
, pp. 179-183
-
-
Hay, N.1
-
2
-
-
33746637660
-
Current development of mTOR inhibitors as anticancer agents
-
Faivre S. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5 (2006) 671-688
-
(2006)
Nat. Rev. Drug Discov.
, vol.5
, pp. 671-688
-
-
Faivre, S.1
-
3
-
-
34347220473
-
Defining the role of mTOR in cancer
-
Guertin D.A. Defining the role of mTOR in cancer. Cancer Cell 12 (2007) 9-22
-
(2007)
Cancer Cell
, vol.12
, pp. 9-22
-
-
Guertin, D.A.1
-
4
-
-
33750058023
-
Upstream of the mammalian target of rapamycin: do all roads pass trough mTOR?
-
Corradetti M.N. Upstream of the mammalian target of rapamycin: do all roads pass trough mTOR?. Oncogene 25 (2006) 6347-6360
-
(2006)
Oncogene
, vol.25
, pp. 6347-6360
-
-
Corradetti, M.N.1
-
5
-
-
3342895823
-
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
-
Sarbassov D.D. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14 (2004) 1296-1302
-
(2004)
Curr. Biol.
, vol.14
, pp. 1296-1302
-
-
Sarbassov, D.D.1
-
6
-
-
81455151255
-
The tuberous sclerosis complex
-
Crino P.B. The tuberous sclerosis complex. N. Engl. J. Med. 355 (2006) 1345-1356
-
(2006)
N. Engl. J. Med.
, vol.355
, pp. 1345-1356
-
-
Crino, P.B.1
-
7
-
-
0043127125
-
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
-
Inoki K. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 1 (2003) 1829-1834
-
(2003)
Genes Dev.
, vol.1
, pp. 1829-1834
-
-
Inoki, K.1
-
8
-
-
0036632368
-
The phosphatidylinositol 3-kinase AKT pathway in human cancer
-
Vivanco I. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
-
(2002)
Nat. Rev. Cancer
, vol.2
, pp. 489-501
-
-
Vivanco, I.1
-
9
-
-
0034648765
-
Angiogenesis in cancer and other diseases
-
Carmeliet. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
-
(2000)
Nature
, vol.407
, pp. 249-257
-
-
Carmeliet1
-
10
-
-
33747488399
-
PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR
-
Bernardi R. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442 (2006) 779-785
-
(2006)
Nature
, vol.442
, pp. 779-785
-
-
Bernardi, R.1
-
11
-
-
0033587146
-
The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
-
Maxwell P.H. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
-
(1999)
Nature
, vol.399
, pp. 271-275
-
-
Maxwell, P.H.1
-
12
-
-
33846080045
-
Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2
-
Li W. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ. Res. 100 (2007) 79-87
-
(2007)
Circ. Res.
, vol.100
, pp. 79-87
-
-
Li, W.1
-
13
-
-
0016724057
-
Rapamycin (AY-22.989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete ans isolation of the active principle
-
Vezina C. Rapamycin (AY-22.989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete ans isolation of the active principle. J. Antibiot. (Tokyo) 28 (1975) 721-726
-
(1975)
J. Antibiot. (Tokyo)
, vol.28
, pp. 721-726
-
-
Vezina, C.1
-
14
-
-
27644436740
-
Maintenance immunosuppression with target of rapamycin inhibitors is associated with a reduced incidence of the de novo malignancies
-
Kauffman H.M. Maintenance immunosuppression with target of rapamycin inhibitors is associated with a reduced incidence of the de novo malignancies. Transplantation 80 (2005) 883-889
-
(2005)
Transplantation
, vol.80
, pp. 883-889
-
-
Kauffman, H.M.1
-
15
-
-
0036174289
-
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
-
Guba M. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8 (2002) 128-135
-
(2002)
Nat. Med.
, vol.8
, pp. 128-135
-
-
Guba, M.1
-
16
-
-
20144367584
-
Sirolimus for Kaposi's sarcoma in renal-transplant recipients
-
Stallone G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 31 (2005) 1317-1323
-
(2005)
N. Engl. J. Med.
, vol.31
, pp. 1317-1323
-
-
Stallone, G.1
-
17
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
Hudes G. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356 (2007) 2271-2281
-
(2007)
N. Engl. J. Med.
, vol.356
, pp. 2271-2281
-
-
Hudes, G.1
-
18
-
-
2942735384
-
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
-
Raymond E. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22 (2004) 2336-2347
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 2336-2347
-
-
Raymond, E.1
-
19
-
-
33750321673
-
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer
-
Hidalgo M. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin. Cancer Res. 12 (2006) 5755-5763
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 5755-5763
-
-
Hidalgo, M.1
-
20
-
-
23944439945
-
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
-
Chan S. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23 (2005) 5314-5322
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 5314-5322
-
-
Chan, S.1
-
21
-
-
34548528069
-
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma
-
Motzer R.J. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J. Clin. Oncol. 25 (2007) 3958-3964
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 3958-3964
-
-
Motzer, R.J.1
-
22
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer R.J. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356 (2007) 115-124
-
(2007)
N. Engl. J. Med.
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
-
23
-
-
0034790016
-
mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
-
Yu K. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 8 (2001) 249-258
-
(2001)
Endocr. Relat. Cancer
, vol.8
, pp. 249-258
-
-
Yu, K.1
-
24
-
-
23944481410
-
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
-
Witzig T.E. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 10 (2005) 5347-5356
-
(2005)
J. Clin. Oncol.
, vol.10
, pp. 5347-5356
-
-
Witzig, T.E.1
-
25
-
-
33847180901
-
Endometrial carcinoma: pathology and genetics
-
Prat J. Endometrial carcinoma: pathology and genetics. Pathology 39 (2007) 72-87
-
(2007)
Pathology
, vol.39
, pp. 72-87
-
-
Prat, J.1
-
26
-
-
16644393813
-
Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression
-
Salvesen H.B. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int. J. Oncol. 25 (2004) 1615-1623
-
(2004)
Int. J. Oncol.
, vol.25
, pp. 1615-1623
-
-
Salvesen, H.B.1
-
27
-
-
24744448247
-
PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma
-
Uegaki K. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol. Rep. 14 (2005) 389-392
-
(2005)
Oncol. Rep.
, vol.14
, pp. 389-392
-
-
Uegaki, K.1
-
28
-
-
33847415365
-
Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model
-
Milam M.R. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am. J. Obstet. Gynecol. 196 (2007) 247e1-247e5
-
(2007)
Am. J. Obstet. Gynecol.
, vol.196
-
-
Milam, M.R.1
-
29
-
-
33750271928
-
Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCIC IND 160
-
(abstract 3003)
-
Oza A.M. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCIC IND 160. Proc. Am. Soc. Clin. Oncol. 24 (2005) (abstract 3003)
-
(2005)
Proc. Am. Soc. Clin. Oncol.
, vol.24
-
-
Oza, A.M.1
-
30
-
-
34447343798
-
Lessons learned in the development of targeted therapy for malignant gliomas
-
Omuro. Lessons learned in the development of targeted therapy for malignant gliomas. Mol. Cancer Ther. 6 (2007) 1909-1919
-
(2007)
Mol. Cancer Ther.
, vol.6
, pp. 1909-1919
-
-
Omuro1
-
31
-
-
23944453425
-
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study
-
Galanis E. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23 (2005) 5294-5304
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 5294-5304
-
-
Galanis, E.1
-
32
-
-
21044431575
-
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
-
Chang S.M. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs 23 (2005) 357-361
-
(2005)
Invest. New Drugs
, vol.23
, pp. 357-361
-
-
Chang, S.M.1
-
33
-
-
35848959875
-
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)
-
Pandya K.J. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J. Thorac. Oncol. 2 (2007) 1036-1041
-
(2007)
J. Thorac. Oncol.
, vol.2
, pp. 1036-1041
-
-
Pandya, K.J.1
-
34
-
-
33845938611
-
A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS)
-
(abstract 9504)
-
Okuno S.H. A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS). Proc. Am. Soc. Clin. Oncol. 24 (2006) (abstract 9504)
-
(2006)
Proc. Am. Soc. Clin. Oncol.
, vol.24
-
-
Okuno, S.H.1
-
35
-
-
33750510023
-
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
-
Duran I. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br. J. Cancer 6 (2006) 1148-1154
-
(2006)
Br. J. Cancer
, vol.6
, pp. 1148-1154
-
-
Duran I1
-
36
-
-
9144233506
-
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
-
Boulay A. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 1 (2004) 252-261
-
(2004)
Cancer Res.
, vol.1
, pp. 252-261
-
-
Boulay, A.1
-
37
-
-
33746651683
-
A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
-
(abstract 4530)
-
Amato R.J. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). Proc. Am. Soc. Clin. Oncol. (2006) 24 (abstract 4530)
-
(2006)
Proc. Am. Soc. Clin. Oncol.
, pp. 24
-
-
Amato, R.J.1
-
38
-
-
35548977012
-
A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
-
(abstract 5107)
-
Jac J. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). Proc. Am. Soc. Clin. Oncol. (2007) 25 (abstract 5107)
-
(2007)
Proc. Am. Soc. Clin. Oncol.
, pp. 25
-
-
Jac, J.1
-
39
-
-
46749158800
-
A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer
-
(abstract 3513)
-
Ellard S. A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 25 (2007) (abstract 3513)
-
(2007)
Proc. Am. Soc. Clin. Oncol.
, vol.25
-
-
Ellard, S.1
-
40
-
-
33846569938
-
Targeting mammalian target of rapamycin (mTOR) for health and diseases
-
Tsang CK. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today 12 (2007) 112-124
-
(2007)
Drug Discov. Today
, vol.12
, pp. 112-124
-
-
Tsang CK1
-
41
-
-
33750238350
-
Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas
-
(abstract 9505)
-
Chawla S.P. Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. Proc. Am. Soc. Clin. Oncol. 24 (2006) (abstract 9505)
-
(2006)
Proc. Am. Soc. Clin. Oncol.
, vol.24
-
-
Chawla, S.P.1
-
42
-
-
37149033966
-
Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial
-
(abstract 10076)
-
Chawla S.P. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial. Proc. Am. Soc. Clin. Oncol. 25 (2007) (abstract 10076)
-
(2007)
Proc. Am. Soc. Clin. Oncol.
, vol.25
-
-
Chawla, S.P.1
-
43
-
-
33646917622
-
Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor
-
(abstract 3033)
-
Rivera V.M. Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor. Proc. Am. Soc. Clin. Oncol. 23 (2005) (abstract 3033)
-
(2005)
Proc. Am. Soc. Clin. Oncol.
, vol.23
-
-
Rivera, V.M.1
-
44
-
-
33645635326
-
A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies
-
(abstract 6631)
-
Feldman E. A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies. Proc. Am. Soc. Clin. Oncol. 23 (2005) (abstract 6631)
-
(2005)
Proc. Am. Soc. Clin. Oncol.
, vol.23
-
-
Feldman, E.1
-
45
-
-
37149010753
-
A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer
-
(abstract 5516)
-
Colombo N. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. Proc. Am. Soc. Clin. Oncol. 25 (2007) (abstract 5516)
-
(2007)
Proc. Am. Soc. Clin. Oncol.
, vol.25
-
-
Colombo, N.1
-
46
-
-
46749117290
-
18F]2-fluoro-desoxy-d-glucose (FDG) positron emission tomography (PET) scan
-
(abstract 9028)
-
18F]2-fluoro-desoxy-d-glucose (FDG) positron emission tomography (PET) scan. Proc. Am. Soc. Clin. Oncol. 23 (2005) (abstract 9028)
-
(2005)
Proc. Am. Soc. Clin. Oncol.
, vol.23
-
-
Sankhala, K.1
-
47
-
-
0041662261
-
Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients
-
Peralba J.M. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin. Cancer Res. 9 (2003) 2887-2892
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 2887-2892
-
-
Peralba, J.M.1
-
48
-
-
35348858663
-
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma
-
Cho D. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin. Genitourin Cancer 5 (2007) 379-385
-
(2007)
Clin. Genitourin Cancer
, vol.5
, pp. 379-385
-
-
Cho, D.1
-
49
-
-
0035744033
-
Mechanisms of resistance to rapamycins
-
Huang S. Mechanisms of resistance to rapamycins. Drug Resist. Updat. 4 (2002) 378-391
-
(2002)
Drug Resist. Updat.
, vol.4
, pp. 378-391
-
-
Huang S1
-
50
-
-
33947538050
-
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
-
Wan X. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 22 (2007) 1932-1940
-
(2007)
Oncogene
, vol.22
, pp. 1932-1940
-
-
Wan, X.1
-
51
-
-
35348917266
-
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency
-
Lu C.H. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin. Cancer Res. 1 (2007) 5883-5888
-
(2007)
Clin. Cancer Res.
, vol.1
, pp. 5883-5888
-
-
Lu, C.H.1
-
52
-
-
33745903146
-
Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells
-
Treeck O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol. Oncol. 102 (2006) 292-299
-
(2006)
Gynecol. Oncol.
, vol.102
, pp. 292-299
-
-
Treeck, O.1
-
53
-
-
33748530840
-
Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer
-
(abstract 564)
-
Carpenter J.T. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 23 (2005) (abstract 564)
-
(2005)
Proc. Am. Soc. Clin. Oncol.
, vol.23
-
-
Carpenter, J.T.1
-
54
-
-
33846404324
-
Prospective FDG-PET and CT assessment of discontinuation of erlotinib (E) or gefitinib (G) in patients with EGFR TKI sensitive non-small cell lung cancer (NSCLC) who subsequently progress radiographically on E or G ("acquired resistance") followed by re-initiation of E or G and the subsequent addition of everolimus (RAD001)
-
(abstract 7065)
-
Riely G.J. Prospective FDG-PET and CT assessment of discontinuation of erlotinib (E) or gefitinib (G) in patients with EGFR TKI sensitive non-small cell lung cancer (NSCLC) who subsequently progress radiographically on E or G ("acquired resistance") followed by re-initiation of E or G and the subsequent addition of everolimus (RAD001). Proc. Am. Soc. Clin. Oncol. 24 (2006) (abstract 7065)
-
(2006)
Proc. Am. Soc. Clin. Oncol.
, vol.24
-
-
Riely, G.J.1
|